Fierce JPM Week - Virtual Agenda has ended

Sign up or log in to bookmark your favorites and sync them to your phone or calendar.

Presentation [clear filter]
Tuesday, January 18

11:10am EST

DCT, hybrid or traditional: Differentiate your study through participant co-creation and design
Accelerate recruitment, increase retention, and ensure diversity with DCT optimized co-creation 

Engaging with participants to influence clinical research design is the standard for industry innovators. Our ability to gain participant feedback in design, throughout the life of the study and at close-out is a way our industry can “be,” not just “say,” we are patient-centric.  
This approach is available to our industry and being utilized today to enhance traditionally designed and decentralized research studies. The benefits are obvious, but the solutions have historically been challenging to collect, listen to and incorporate. That is now changing via the intersection of participant engagement science, decentralization, and digital technologies.  
This session will explore how you can utilize this approach to differentiate your research study and be patient-centric. 

avatar for John Reites

John Reites

Co-founder and CEO, THREAD
Executive intrapreneur turned digital health entrepreneur, his career spans nearly 20 years leading global drug development, digital health and decentralized clinical trials (DCTs) for life science organizations.As Co-founder and CEO of THREAD, John leads the global organization to... Read More →

Tuesday January 18, 2022 11:10am - 11:30am EST

2:40pm EST

Challenge the rules of security: Transform the threat surface to proactive control
We’ve seen a dramatic increase in distributed workforce, telehealth and usage of cloud applications across healthcare providers. And healthcare organizations continue to be targeted by cybercriminals, and now with remote endpoints, they have more ways to break in than ever before. Historically, endpoint security has been a zero-sum game—with the odds inevitably stacked against IT. But rather than protecting devices, what if you could control their security ahead of time?

In this session, see how Chrome OS and Chrome Browser are secure by design—embedding security into every workflow to provide proactive protection for your staff, devices, applications, and patient information, wherever work happens. This is cloud-first security that will help healthcare providers thrive moving forward.

avatar for Mike Puzen

Mike Puzen

Head of GTM, Chrome Enterprise, Google
Mike has been a technology thought leader for the past 15 years. He has focused on Retail, Manufacturing and Healthcare for most of his career with IBM, Sandisk, Lenovo and now Google. The goal for him has always been to push the boundaries of innovation at the customer experience... Read More →

Tuesday January 18, 2022 2:40pm - 2:50pm EST

2:50pm EST

Improving Translational Medicine by Humanization of Mouse Models: The World’s Largest Pipeline
GemPharmatech’s mission is to accelerate innovation and understanding of biological systems to better treat human diseases. We have created over 17,000 mouse models, including Immunodeficient lines (NCG and over 10 derivatives), over 80 humanized models for Immune Checkpoint research, and plan to humanize of 600 new mouse genes in the coming year. We also offer products for research in all areas of biology including neuroscience, metabolism, obesity, cardiovascular and immunology.

avatar for Mark Moore

Mark Moore

CEO, GemPharmatech
Dr. Mark Moore, CEO at GemPharmatech, is a pioneer in the use of genetically modified mice for pharmaceutical and basic research. He has worked in immunology, oncology, animal model construction and gene editing. Before joining GemPharmatech, he was a co-founder and CSO of Deltagen... Read More →

Tuesday January 18, 2022 2:50pm - 3:10pm EST
Wednesday, January 19

11:15am EST

Biosciences Commercial Supply (BCS) and OEM
Get to market faster with a better product, increased revenues, and an optimized workflow.
For Diagnostic life science companies that work to make the world healthier, the race to market depends on finding a supplier partner that can evaluate your needs, customize, and deliver on quality. In a post-COVID world, finding a partner that can also create value and maintain security of supply is a key differentiator. This session will explore 5 things the most successful diagnostics companies evaluate when selecting a supplier-partner.

avatar for Jeremy Schroeder

Jeremy Schroeder

Sr. Director, Global Commercial OEM, Thermo Fisher Scientific
Jeremy Schroeder is the Sr. Director, Global Commercial OEM for Thermo Fisher Scientific. His professional passion is helping our diagnostics, life science, and therapeutic customers accelerate product development timelines, develop the best technologies, and maximize revenue by leveraging... Read More →

Wednesday January 19, 2022 11:15am - 11:30am EST

2:30pm EST

Becoming Data-Centric — A Conversation with Global R&D Leaders Working in a Modern Digital Ecosystem
Leading biopharma companies are universally undertaking digital transformation efforts to stay ahead of scientific and business opportunities. Becoming data-centric is essential to operate as a nimble, fast-moving, highly-connected, and information-centered R&D organization. In this conversation, two global biotech leaders share how their organizations evolved how their R&D teams work. They share how the transformation process is easier — and more impactful — than expected.

avatar for David Sexton

David Sexton

Senior Director, Genome Technologies and Informatics, Biogen
 David Sexton is Biogen's Senior Director of Genome Technology and Informatics and handles all NGS sequencing, NGS data analysis and information systems. Sexton has more than 25 years of experience in genomics and informatics and was the Head of Genome Informatics at NIBR where he... Read More →
avatar for Loren Perelman

Loren Perelman

Head of Enterprise Professional Services, Benchling
Loren Perelman spent much of his career focused on helping organizations make better use of their primary asset, data, by improving methods of collection and utilization. Prior to Benchling, Perelman was Vice-President of Scientific Solutions at Riffyn, working with various customers... Read More →

Wednesday January 19, 2022 2:30pm - 2:50pm EST

3:30pm EST

Accelerate innovation at the intersection of biopharma and healthcare
In biopharma, one-off digital apps for patient support, access or digital therapeutics are now commonplace. While these are a step in the right direction, they solve one problem at a time. Collectively they end up creating a lot of digital noise in the healthcare system, disconnected with the patient health record and clinical operations and produce mixed overall results. To make the leap to personalized, patient-centric medicine, biopharma needs to connect their digital innovations, in partnership with healthcare, to clinical and operational workflows and leverage the insights from a unified patient record. In doing so, biopharma can enable an environment of collaboration, insight, learning, and accelerated innovation for all healthcare stakeholders; and improve the experiences for clinicians and patients.

Come join our session to know how you can accelerate innovation at the intersection of biopharma and healthcare.

avatar for Abhinav Shashank

Abhinav Shashank

Co-Founder & CEO, Innovaccer
Abhinav Shashank is the CEO and co-founder of Innovaccer, a leading San Francisco-based healthcare technology company. He built the foundation for Innovaccer’s success as a leader in population health management and machine learning-oriented healthcare solutions recognized by Gartner... Read More →
avatar for Smriti Khera, Ph.D.

Smriti Khera, Ph.D.

Senior Director, Lifesciences, Innovaccer
Smriti currently leads the Life Sciences marketing team at Innovaccer. She has 15+ years of leadership across R&D, business strategy and marketing in biopharma, research instrumentation and high tech industries. She holds a PhD in Pharmaceutical Sciences from the University of Arizona... Read More →

Wednesday January 19, 2022 3:30pm - 3:50pm EST
Thursday, January 20

10:50am EST

Secure Your R&D Content Migration with the Content Cloud
Life Sciences organizations always look to innovate in order to grow their organization. Often times, innovation occurs through acquisition. But, acquiring highly regulated content isn't always easy to integrate with your organization.

That's where Box comes in. Box enables you to accelerate post-merger-integration (PMI) cycle times with faster ingestion of newly acquired regulated and non-regulated R&D information in a secure, GxP environment.
Box and USDM partner on Thursday, January 20, 10:50am - 11:10 am to uncover high-level trends, challenges, and key learning about streamlining R&D processes and post-merger content migration.

Join to hear how to:
  • Streamline the complexity of regulated content migration from one entity to another
  • Ensure regulatory compliance while migrating content with Box GxP

avatar for Manu Vohra

Manu Vohra

Managing Director, Life Sciences, Box
Manu Vohra is the Global lead for Life Sciences and Go-To-Market strategy for Cloud Content Management at http://Box.com . After 2 decades of deploying ECM solutions in a regulated industry, I'm spending my efforts supporting Life Sciences companies to ride the Digital Transformation wave and fully leverage the micro content service offerings of a modern Content Platform at Box... Read More →
avatar for Ganesh Visvanathan

Ganesh Visvanathan

Cloud Product Manager, USDM Life Sciences
Ganesh is a digital transformation and application modernization leader with 25+ years of technology and data science experience. His expertise includes strategy, systems design, product development, data management, and risk management in the life sciences, energy, financial, and... Read More →

Thursday January 20, 2022 10:50am - 11:10am EST

11:10am EST

R&D in an Age of Multiplying Modalities and Targets
mRNA is the latest in a wave of new modalities that expand our ability to intervene in disease. Even established modalities see a broadening reach as omics and AI-enabled discovery open new targets and diseases to attack. The multiplicative expansion of modalities, targets, and diseases creates many new opportunities but challenges the traditional blockbuster model. We examine the evolution of the R&D landscape and its drivers, as the number and diversity of approaches grow and consider implications for development strategy, clinical trials, and ROI.

avatar for Michael Ward

Michael Ward

Global Head of Life Sciences & Healthcare Thought Leadership, Clarivate
Mike Ward serves as Global Head of Life Sciences & Healthcare Thought Leadership, Clarivate. As both an award-winning journalist and analyst, Mike has been writing, analyzing and commenting on the life sciences industry for more than 35 years. He has held editorial and content leadership... Read More →
avatar for Kenneth Beers, Ph.D.

Kenneth Beers, Ph.D.

Partner-Consulting, Clarivate
Ken is a Partner in Clarivate’s Commercial Consulting practice serving life sciences clients on matters related to portfolio strategy and asset development and commercialization. Ken works closely with Clarivate data analytics and bioinformatics experts to bring scientific, clinical... Read More →

Thursday January 20, 2022 11:10am - 11:30am EST